Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.76 |
| ▸ | RAB9A | P51151 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.61 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.61 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11410738 | 1.00 | NPC1 (0.76) | NPC1SMN1; SMN2RAB9AMAPTMAPK1 | |
| SCHEMBL11407159 | 1.00 | NPC1 (0.76) | NPC1SMN1; SMN2RAB9AMAPTMAPK1 | |
| SCHEMBL9456557 | 0.97 | SMN1; SMN2 (0.71) | NPC1SMN1; SMN2RAB9AMAPTMAPK1 | |
| SCHEMBL5026796 | 0.92 | SMN1; SMN2 (0.64) | NPC1SMN1; SMN2RAB9AMAPTMAPK1 | |
| SCHEMBL583921 | 0.87 | — | — | |
| SCHEMBL23736058 | 0.87 | NPC1 (1.00) | NPC1SMN1; SMN2RAB9AMAPTMAPK1 | |
| SCHEMBL3076504 | 0.87 | NPC1 (1.00) | NPC1SMN1; SMN2RAB9AMAPTMAPK1 | |
| SCHEMBL2377367 | 0.87 | NPC1 (1.00) | NPC1SMN1; SMN2RAB9AMAPTMAPK1 | |
| SCHEMBL8165938 | 0.87 | NPC1 (1.00) | NPC1SMN1; SMN2RAB9AMAPTMAPK1 | |
| SCHEMBL6850969 | 0.84 | SMN1; SMN2 (0.94) | NPC1SMN1; SMN2RAB9AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350116-A | Method for synthesizing itaconic acid compound | 南京工业大学 | 2025-01-24 | — | — | CN | disclosed |
| CN-115385858-B | Photocatalytic preparation method of 2-phenyl-2H-indazole-3-carboxamide compound | 河南师范大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-115403519-B | Synthesis method of N-substituted isonicotinamide compound driven by visible light | 河南师范大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-116807914-A | Oil control composition and application thereof in cosmetics | 珠海姗拉娜化妆品有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-115403519-A | Synthesis method of N-substituted isonicotinamide compound driven by visible light | 河南师范大学 | 2022-11-29 | — | — | CN | disclosed |
| EP-2670765-B1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| CN-103429607-B | There is the triterpenoid that C-17 and C-3 of HIV maturation inhibit activities is modified | BRISTOL-MYERS SQUIBB CO. (US) | 2016-02-17 | — | — | CN | disclosed |
| US-20140343000-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| US-8846647-B2 | C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| EP-0275317-B1 | PROCESS FOR PRODUCING STEREOREGULAR POLYOLEFINS | TOSOH CORPORATION (JP) | 1990-11-28 | — | — | EP | disclosed |
| EP-0275317-A1 | PROCESS FOR PRODUCING STEREOREGULAR POLYOLEFINS | TOSOH CORPORATION (JP) | 1988-07-27 | — | — | EP | disclosed |
| US-4617360-A | SOLID CATALYST COMPLEX FROM OXYGEN-CONTAINING MAGNESIUM COMPOUNDS, OXYGEN-CONTAINING TITANUIM COMPOUNDS AND ORGANOALUMINUM HALIDE COMPOUNDS | SOLVAY & CIE. (BE) | 1986-10-14 | — | — | US | disclosed |
| US-4292200-A | NON-HALIDE ORGANIC OXYGENATED COMPOUNDS OF MAGNESIUM AND TRANSITION METAL, ORGANOALUMINUM HALIDE | SOLVAY & CIE (BE) | 1981-09-29 | — | — | US | disclosed |
| EP-0000007-B1 | PROCESS FOR THE POLYMERISATION OF ALPHA-OLEFINS AND METHOD FOR PREPARING SOLID CATALYTIC COMPLEXES FOR USE IN THIS POLYMERISATION PROCESS | SOLVAY & Cie (Société Anonyme) (BE) | 1981-05-20 | — | — | EP | disclosed |
| US-4258159-A | USING COORDINATION CATALYST | SOLVAY & CIE (BE) | 1981-03-24 | — | — | US | disclosed |
| US-4192772-A | FOR ALPHA-OLEFIN POLYMERIZATION, COMPLEX OF ALUMINUM, ZIRCONIUM, TITANIUM AND MAGNESIUM COMPOUNDS | SOLVAY & CIE (BE) | 1980-03-11 | — | — | US | disclosed |
| US-4187315-A | N-alkyl(and cycloalkyl)oxamic acid and derivatives as inhibitors of glycolic acid oxidase | MERCK & CO., INC. (US) | 1980-02-05 | — | — | US | disclosed |
| EP-0000007-A1 | Process for the polymerisation of alpha-olefins and method for preparing solid catalytic complexes for use in this polymerisation process | SOLVAY & Cie (Société Anonyme) (BE) | 1978-12-20 | — | — | EP | disclosed |
| US-4109071-A | COMPLEX ORGANO-METALLIC SOLID CATALYST CONTAINING MAGNESIUM, TITANIUM, ZIRCONIUM AND ALUMINUM | SOLVAY & CIE. (BE) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, HSD17B7 | NPC1 1181/4885SMN1; SMN2 4441/4885RAB9A 2014/4885 |
| US-20140343000-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, HSD17B7 | NPC1 1181/4885SMN1; SMN2 4441/4885RAB9A 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.